Kymera Therapeutics Reports Positive KT-621 Phase 1b Atopic Dermatitis Trial Results

Kymera Therapeutics presented positive results from its BroADen Phase 1b atopic dermatitis trial for KT-621, a first-in-class oral STAT6 degrader. The data showed consistent impact across multiple pharmacodynamic and clinical measures, with deep STAT6 degradation and robust reductions in Type 2 inflammatory biomarkers. Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, are ongoing with data expected by mid-2027 and late-2027, respectively.